IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation
Cells · 2025
DOI: 10.3390/cells14141086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Konstantinos Mengrelis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria. Hauptthemen laut MEDLINE: Interleukin-2, Skin Transplantation, Graft Rejection, Immunoglobulin G. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, FWF Austrian Science Fund, Austrian Science Fund.
Abstract (Originalsprache)
Antibody-mediated rejection (ABMR) caused by donor-specific Abs (DSAs) is still the leading cause of late graft loss following clinical organ transplantation, and effective strategies to combat ABMR are still elusive. We previously showed that rIL-2 complexed with anti-IL-2 mAb clone JES6-1A12 (IL-2 cplx) leads to the selective expansion of regulatory T cells (Tregs) and the prolonged survival of MHC-mismatched skin allografts. Although the grafts were eventually rejected, mice failed to develop DSAs. Here, we investigated the impact of IL-2 cplx on the humoral response and germinal center (GC) reaction during allograft rejection. IL-2 cplx treatment prevents Bcl-6 upregulation, leading to suppressed development of GC T and B cells. The IL-2 cplx-induced impairment of GC development limits IgG allo-Ab production but allows for IgM synthesis. By employing a hapten–carrier system to investigate affinity maturation, we found that IL-2 cplx induces a distinct shift in specific Ab production favoring low-affinity IgM while simultaneously decreasing IgG responses. These findings illuminate the potential of IL-2 cplx therapy for inducing humoral tolerance, potentially paving the way for refining strategies aimed at preventing and treating ABMR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria.
- Department of General Surgery, Division of Transplantation, Medical University of Vienna, 1090 Vienna, Austria.
- Center for Biomedical Research and Translational Surgery, Medical University of Vienna, 1090 Vienna, Austria.
- Division of Immunobiology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090 Vienna, Austria.
- Center for Medical Statistics, Informatics and Intelligent Systems, Section for Medical Statistics, Medical University of Vienna, 1090 Vienna, Austria.
- Garvan Institute of Medical Research, Immunology Division, Sydney, NSW 2010, Australia.
ORCID-Profile: Romy Steiner, Anna M Weijler, Laurenz Wolner, Valentina Stolz, Florian Frommlet, Jonathan Sprent, Hannes Stockinger, Nina Pilat
Förderung
- NIAID NIH HHS
- FWF Austrian Science Fund
- Austrian Science Fund
Zitieren
APA
Mengrelis, K., Wiletel, M., Steiner, R., Weijler, A. M., Wolner, L., Stolz, V., Nikolic, M., Simon, D., Frommlet, F., Sprent, J., Stockinger, H., & Pilat, N. (2025). IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation. Cells. https://doi.org/10.3390/cells14141086
Vancouver
Mengrelis K, Wiletel M, Steiner R, Weijler AM, Wolner L, Stolz V, et al. IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation. Cells. 2025. doi:10.3390/cells14141086
BibTeX
@article{Mengrelis2025,
author = {Mengrelis, Konstantinos and Wiletel, Mario and Steiner, Romy and Weijler, Anna M and Wolner, Laurenz and Stolz, Valentina and Nikolic, Milos and Simon, Daniel and Frommlet, Florian and Sprent, Jonathan and Stockinger, Hannes and Pilat, Nina},
title = {IL-2 Complex Therapy Mitigates Humoral Rejection of Fully Mismatched Skin Allografts by Inhibiting IgG Alloantibody Formation},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14141086}
}
EUVIMED